You are here
- Home
- Therapy Areas
- Oncology/Infection
A randomised placebo-controlled trial of concurrent cediranib [ZD2171] (with platinum-based chemotherapy) and concurrent and maintenance cediranib in women with platinum-sensitive relapsed ovarian cancer.
- Disease
- colorectal cancer
- Drug Name
- RECENTIN
- Generic Name
- AZD2171
- Sponsor
- AstraZeneca
- Drug Status
- In Development
- Phase
- IIIa
- Start Date
- Dec 4, 2007
- Study Name
- D8480C00037
- Study Id
- D8480C00037
- ClinicalTrials.gov ID
- NCT00544973
- Recruiting Status
- Open
- Protocol Status
- Not Available
- Report Status
- Not Available
